ReviewInternational journal of molecular sciences2017
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 60 citations in OpenAlex.
- Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.International journal of cancer · 2021Trial
- Article
- Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.Heliyon · 2025Article
- Prognosis and risk factor assessment of patients with advanced lung cancer with low socioeconomic status: model development and validation.BMC cancer · 2024Observational
- Does needle gauge affect complication rates of computed tomography-guided lung biopsy?Journal of thoracic disease · 2024Article
- Investigating the role of let-7a microRNA in cisplatin sensitivity of A549 lung cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- The Effect of MiR320a on Lung Cancer.MicroRNA (Shariqah, United Arab Emirates) · 2024Review
- Impact of Different Treatment Regimens and Timeframes in the Plasmatic Metabolic Profiling of Patients with Lung Adenocarcinoma.Metabolites · 2023Article
- Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.BMC cancer · 2023Article
- In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.Cancer cell international · 2023Article
- Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Genistein-induced mitochondrial dysfunction and FOXO3a/PUMA expression in non-small lung cancer cells.Pharmaceutical biology · 2022Article
- Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients.Frontiers in oncology · 2022Article
- Negative correlations of psychological distress with quality of life and immunotherapy efficacy in patients with advanced NSCLC.American journal of cancer research · 2022Article
- Theabrownins Produced via Chemical Oxidation of Tea Polyphenols Inhibit Human Lung Cancer CellsFrontiers in nutrition · 2022Article
- The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis.Heliyon · 2021Article
- Identification of the molecular function of tripartite motif containing 58 in human lung cancer.Oncology letters · 2021Article
- Use of cucurbitacins for lung cancer research and therapy.Cancer chemotherapy and pharmacology · 2021Review
- Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinoma.Translational cancer research · 2021Article
- Heterodimeric IL-15 in Cancer Immunotherapy.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.